Literature DB >> 16804062

Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.

Eric C M Ho1, Karen S L Lam, Yuk Shan Chen, Johnny C W Yip, Meena Arvindakshan, Shin-Ichiro Yamagishi, Soroku Yagihashi, Peter J Oates, Craig A Ellery, Stephen S M Chung, Sookja K Chung.   

Abstract

The exaggerated flux through polyol pathway during diabetes is thought to be a major cause of lesions in the peripheral nerves. Here, we used aldose reductase (AR)-deficient (AR(-/-)) and AR inhibitor (ARI)-treated mice to further understand the in vivo role of polyol pathway in the pathogenesis of diabetic neuropathy. Under normal conditions, there were no obvious differences in the innervation patterns between wild-type AR (AR(+/+)) and AR(-/-) mice. Under short-term diabetic conditions, AR(-/-) mice were protected from the reduction of motor and sensory nerve conduction velocities observed in diabetic AR(+/+) mice. Sorbitol levels in the sciatic nerves of diabetic AR(+/+) mice were increased significantly, whereas sorbitol levels in the diabetic AR(-/-) mice were significantly lower than those in diabetic AR(+/+) mice. In addition, signs of oxidative stress, such as increased activation of c-Jun NH(2)-terminal kinase (JNK), depletion of reduced glutathione, increase of superoxide formation, and DNA damage, observed in the sciatic nerves of diabetic AR(+/+) mice were not observed in the diabetic AR(-/-) mice, indicating that the diabetic AR(-/-) mice were protected from oxidative stress in the sciatic nerve. The diabetic AR(-/-) mice also excreted less 8-hydroxy-2'-deoxyguanosine in urine than diabetic AR(+/+) mice. The structural abnormalities observed in the sural nerve of diabetic AR(+/+) mice were less severe in the diabetic AR(-/-) mice, although it was only mildly protected by AR deficiency under short-term diabetic conditions. Signs of oxidative stress and functional and structural abnormalities were also inhibited by the ARI fidarestat in diabetic AR(+/+) nerves, similar to those in diabetic AR(-/-) mice. Taken together, increased polyol pathway flux through AR is a major contributing factor in the early signs of diabetic neuropathy, possibly through depletion of glutathione, increased superoxide accumulation, increased JNK activation, and DNA damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804062     DOI: 10.2337/db05-1497

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

1.  Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.

Authors:  Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Yury Maksimchyk; Tamara M Kuchmerovska; Jerry L Nadler; Irina G Obrosova
Journal:  Exp Neurol       Date:  2011-04-16       Impact factor: 5.330

2.  Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.

Authors:  Irina G Obrosova; Roman Stavniichuk; Viktor R Drel; Hanna Shevalye; Igor Vareniuk; Jerry L Nadler; Robert E Schmidt
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Mitochondrial stress and the pathogenesis of diabetic neuropathy.

Authors:  Paul Fernyhough; Subir K Roy Chowdhury; Robert E Schmidt
Journal:  Expert Rev Endocrinol Metab       Date:  2010-01-01

4.  Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Hanna Shevalye; Hiroko Hirooka; Jerry L Nadler; Irina G Obrosova
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

5.  12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Alexander A Obrosov; Viktor R Drel; Jerry L Nadler; Irina G Obrosova; Mark A Yorek
Journal:  J Diabetes Mellitus       Date:  2013-08

6.  New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}.

Authors:  Viktor R Drel; Sergey Lupachyk; Hanna Shevalye; Igor Vareniuk; Weizheng Xu; Jie Zhang; Nicholas A Delamere; Mohammad Shahidullah; Barbara Slusher; Irina G Obrosova
Journal:  Endocrinology       Date:  2010-03-31       Impact factor: 4.736

7.  Novel role for aldose reductase in mediating acute inflammatory responses in the lung.

Authors:  Thyyar M Ravindranath; Phyllus Y Mong; Radha Ananthakrishnan; Qing Li; Nosirudeen Quadri; Ann Marie Schmidt; Ravichandran Ramasamy; Qin Wang
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

8.  Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.

Authors:  Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan A Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Seth R Bell; John T Groves; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2007-12       Impact factor: 4.101

9.  Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production.

Authors:  Liang Zhang; Cuijuan Yu; Francisco E Vasquez; Nadya Galeva; Isaac Onyango; Russell H Swerdlow; Rick T Dobrowsky
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

10.  Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.